José Rodríguez

发表

Serum β-2 Microglobulin Levels Are a Significant Prognostic Factor in Philadelphia Chromosome-positive Chronic Myelogenous Leukemia

H. Kantarjian, J. Cortes, M. Talpaz, 2000 .

p16INK4a Is Selectively Silenced in the Tumoral Progression of Mycosis Fungoides

M. Piris, M. Mateo, I. Navas, 2002, Laboratory Investigation.

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma

P. Galan, J. Besalduch, J. Rodríguez, 2014, OncoTargets and therapy.

Frontline autologous stem cell transplantation in high‐risk peripheral T‐cell lymphoma: a prospective study from The Gel‐Tamo Study Group

J. Rodríguez, R. Arranz, A. Gutiérrez, 2007, European journal of haematology.

Prolonged survival of patients with angioimmunoblastic T‐cell lymphoma after high‐dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience

J. Rodríguez, J. Ribera, J. Moraleda, 2007, European journal of haematology.

Dose‐escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem‐cell transplantation in poor‐risk aggressive B‐cell lymphoma: a prospective study from the GEL–TAMO Study Group

J. Rodríguez, J. Lahuerta, M. Hernandez, 2008, European journal of haematology.

Diffuse large B-cell lymphoma in the older.

G. Pérez-Manga, A. Gutiérrez, J. Rodriguez, 2011, Critical reviews in oncology/hematology.

Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.

B. Martínez-Delgado, G. Pérez-Manga, A. Gutiérrez, 2009, Critical reviews in oncology/hematology.

Therapeutic concepts in mantle cell lymphoma

F. Cabanillas, S. Fernández de Mattos, A. Obrador-Hevia, 2010, European journal of haematology.

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.

C. Solano, J. Rodríguez, J. Lahuerta, 2007, Haematologica.

New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO)

A. Salar, P. Abrisqueta, J. Sancho, 2019, British journal of haematology.

High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.

A. López-Guillermo, J. Sierra, J. Rodríguez, 2003, Haematologica.

Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL‐TAMO experience

J. Rodríguez, J. Lahuerta, A. Gutiérrez, 2008, Hematological oncology.

Differential prognostic impact of GELTAMO‐IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm

Juan F. García, A. Salar, J. Sancho, 2018, British Journal of Haematology.

Molecular biology of mantle cell lymphoma: from profiling studies to new therapeutic strategies.

S. Fernández de Mattos, P. Villalonga, A. Obrador-Hevia, 2009, Blood reviews.

Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B‐cell lymphomas

Marcos González, J. Hernández, M. Piris, 2009, Cancer.

Primary mediastinal B-cell lymphoma: Treatment and therapeutic targets

M. Piris, J. Rodríguez, A. Gutiérrez, 2008, Leukemia & lymphoma.

Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series

Juan F. García, A. Salar, M. Piris, 2012, Leukemia & lymphoma.

classical Hodgkin lymphoma A molecular risk score based on 4 functional pathways for advanced

Juan F. García, A. Salar, M. Piris, 2011 .

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era

Juan F. García, A. López-Guillermo, A. Salar, 2019, European journal of haematology.

Validation of the NCCN‐IPI for diffuse large B‐cell lymphoma (DLBCL): the addition of β2‐microglobulin yields a more accurate GELTAMO‐IPI

Juan F. García, A. López-Guillermo, A. Salar, 2017, British journal of haematology.

Gemcitabine and Oxaliplatinum (GemOx): An Effective Regimen in Patients with Refractory and Relapsing Hodgkin Lymphoma

P. Galan, J. Rodríguez, J. Bargay, 2012 .

Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma

J. Pons, Jordi Martínez, J. Besalduch, 2006, Leukemia & lymphoma.

Efficacy of the GemOx‐R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma

L. Belayachi, S. Fernández de Mattos, P. Villalonga, 2016, British journal of haematology.

Should rituximab be used prior to autologous stem-cell transplantation for non-Hodgkin's lymphoma?

J. Rodríguez, José Rodríguez, 2005, Nature Clinical Practice Oncology.

Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphomas

J. Rodríguez, P. Corradini, José Rodríguez, 2013 .

Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma

S. Fernández de Mattos, Jordi Martínez, J. Rodríguez, 2007, Leukemia & lymphoma.

Front-Line Autologous Stem Cell Transplantation (ASCT) in Primary Mediastinal Large B-Cell Lymphoma: The GEL-TAMO Experience.

J. Rodríguez, J. Lahuerta, J. C. García-Ruiz, 2006 .

Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma

J. Hernández, M. Piris, J. Rodríguez, 2009, Leukemia & lymphoma.

Frontline autologous stem cell transplantation for peripheral T-cell lymphoma

J. Rodríguez, A. Gutiérrez, José Rodríguez, 2009, Expert review of hematology.

Impact o f H igh-Dose C hemotherapy o n P eripheral T -Cell Lymphomas

M. Munsell, F. Cabanillas, B. Andersson, 2001 .

Phase II Study of Paclitaxel in Combination with Mitoxantrone and Ifosfamide/Mesna for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma after Failure to Cytarabine/Cisplatin Combination

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Investigational New Drugs.